Intervention with MLKL decreased neutrophil death and protected mice against <i>E. coli</i> pneumonia. by Qinyu Luo (13000956)

Mechlorethamine gel causes epithelium thinning, epithelium-stroma separation, and decreased total stroma cell count. by Ana M. Sandoval-Castellanos (11611315)

“…<p>A) Epithelium thickness decreased, and B) the percentage of epithelium-stroma separation increased after NM exposure. …”

Table 3_Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits.docx by Linda S. Barter (21466916)

Image 2_Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits.jpeg by Linda S. Barter (21466916)

Image 1_Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits.jpeg by Linda S. Barter (21466916)

RipU^K60 decreases microtubule abundance at 48 hours post infiltration. by Rachel Hiles (20477573)

“…(B) Heterologous expression of RipU^K60 significantly decreased microtubule number compared to controls at 48 hpi in <i>N</i>. …”

Increase in physical activity (100 step, 500 steps or 1000 steps) after the challenge according to decrease in screen time < or ≥60 minutes. by Annaëlle Le Steunf (19838110)

The spike-in of synthetic hsa-lest-7a-5p miRNA decreases the Ct Values of extracted small RNA samples. by Marc Van Der Hofstadt (1423027)

<i>Ctsz</i>^{<i>−/−</i>} mice have higher lung burden and earlier spleen dissemination during acute infection followed by greater chronic inflammation and mortality risk.... by Rachel K. Meade (22216529)

Subjects:

Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

Subjects:

Data cleaning and preparation algorithm. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Results of the mediation model test for the elevated inhibition function in the relationship between elevated mindfulness level and decreased mobile phone addiction index. by Jizhao Li (5856650)